Evidence map›Paper›PMID 19903920›Full record

ArticleJAMA2009

Major lipids, apolipoproteins, and risk of vascular disease.

Emerging Risk Factors Collaboration, Emanuele Di Angelantonio, Nadeem Sarwar, Philip Perry, Stephen Kaptoge, Kausik K Ray, Alexander Thompson, Angela M Wood, Sarah Lewington, Naveed Sattar and 4 more

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in JAMA, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,125 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,125citing papers in PubMed, 9 pooled it
74.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01687686 unknown statusnot on this map

Differential Effects of Total Cholesterol, Non-HDL Cholesterol and Triglycerides on Initial Presentation of Specific Cardiovascular Diseases (a CALIBER Study)

TypeobservationalSponsorUniversity College, LondonRan2001 to 2012Enrolled175,872ConditionsStable Angina, Unstable Angina, Non ST Elevation Myocardial Infarction, ST Elevation Myocardial Infarction
NCT02998918 nacompletednot on this mapstarted 2016, after this paper: background citation

Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL

TypeinterventionalSponsorUniversity of South CarolinaRan2016 to 2020Enrolled21ConditionsInflammation, Atherosclerosis, Cardiovascular DiseaseArmsPolyResveratrol Supplementation, Curcumin Supplementation
3 · Its place in the literature

Who cites it

1,125 citing papers in PubMed, 9 syntheses or guidelines pooled it, 2,738 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1,065 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Emerging Risk Factors Collaboration
Emanuele Di Angelantonio
Nadeem Sarwar
Philip Perry
Stephen Kaptoge
Kausik K Ray
Alexander Thompson
Angela M Wood
Sarah Lewington
Naveed Sattar
Chris J Packard
Rory Collins
Simon G Thompson
John Danesh

Funding

British Heart Foundation RG/07/008/23674British Heart Foundation RG/08/013/25942British Heart Foundation RG/08/014British Heart Foundation RG/08/014/24067Medical Research Council G0100222Medical Research Council G0401527Medical Research Council G0501792Medical Research Council G0600705Medical Research Council G19/35Medical Research Council G8802774Medical Research Council MC_U105260792Medical Research Council MC_U137686851Medical Research Council MC_U137686853Medical Research Council MC_U137686857Wellcome Trust
6 · The paper itself

Abstract

contextAssociations of major lipids and apolipoproteins with the risk of vascular disease have not been reliably quantified.

objectiveTo assess major lipids and apolipoproteins in vascular risk. DESIGN, SETTING, AND

participantsIndividual records were supplied on 302,430 people without initial vascular disease from 68 long-term prospective studies, mostly in Europe and North America. During 2.79 million person-years of follow-up, there were 8857 nonfatal myocardial infarctions, 3928 coronary heart disease [CHD] deaths, 2534 ischemic strokes, 513 hemorrhagic strokes, and 2536 unclassified strokes.

main outcome measuresHazard ratios (HRs), adjusted for several conventional factors, were calculated for 1-SD higher values: 0.52 log(e) triglyceride, 15 mg/dL high-density lipoprotein cholesterol (HDL-C), 43 mg/dL non-HDL-C, 29 mg/dL apolipoprotein AI, 29 mg/dL apolipoprotein B, and 33 mg/dL directly measured low-density lipoprotein cholesterol (LDL-C). Within-study regression analyses were adjusted for within-person variation and combined using meta-analysis.

resultsThe rates of CHD per 1000 person-years in the bottom and top thirds of baseline lipid distributions, respectively, were 2.6 and 6.2 with triglyceride, 6.4 and 2.4 with HDL-C, and 2.3 and 6.7 with non-HDL-C. Adjusted HRs for CHD were 0.99 (95% CI, 0.94-1.05) with triglyceride, 0.78 (95% CI, 0.74-0.82) with HDL-C, and 1.50 (95% CI, 1.39-1.61) with non-HDL-C. Hazard ratios were at least as strong in participants who did not fast as in those who did. The HR for CHD was 0.35 (95% CI, 0.30-0.42) with a combination of 80 mg/dL lower non-HDL-C and 15 mg/dL higher HDL-C. For the subset with apolipoproteins or directly measured LDL-C, HRs were 1.50 (95% CI, 1.38-1.62) with the ratio non-HDL-C/HDL-C, 1.49 (95% CI, 1.39-1.60) with the ratio apo B/apo AI, 1.42 (95% CI, 1.06-1.91) with non-HDL-C, and 1.38 (95% CI, 1.09-1.73) with directly measured LDL-C. Hazard ratios for ischemic stroke were 1.02 (95% CI, 0.94-1.11) with triglyceride, 0.93 (95% CI, 0.84-1.02) with HDL-C, and 1.12 (95% CI, 1.04-1.20) with non-HDL-C.

conclusionLipid assessment in vascular disease can be simplified by measurement of either total and HDL cholesterol levels or apolipoproteins without the need to fast and without regard to triglyceride.

Indexed as

ApolipoproteinsCholesterol, HDLCoronary DiseaseFemaleHumansLipidsMaleMiddle AgedProportional Hazards ModelsRegression AnalysisRisk FactorsStrokeTriglyceridesVascular DiseasesApolipoproteinsCholesterol, HDLLipidsTriglycerides

Identifiers

PMID19903920
PMCPMC3284229
OpenAlexW2127427274

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.